File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines

TitleChronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines
Authors
KeywordsTh1 cell
T-regulatory cell
Th2 cell
macrophage
Chronic prostatitis/chronic pelvic pain syndromes
prostate cancer
Th17 cell
Issue Date2020
Citation
Fundamental and Clinical Pharmacology, 2020, v. 34, n. 2, p. 160-172 How to Cite?
Abstract© 2019 Société Française de Pharmacologie et de Thérapeutique Prostate cancer and prostatitis are both significant health concerns. A large number of studies have established that the occurrence of the two is closely related. However, the most common prostatitis, type III chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS), is reported to not correlate with the occurrence of prostate cancer. Although the etiology of CP/CPPS is unknown, it may be related to the autoimmune mechanism favored by most studies. Manipulating the immune system and targeting tumor microenvironment are promising new methods for the treatment of prostate cancer. Therefore, this review focuses on the immune cells and cytokines of CP/CPPS and prostate cancer from the perspective of biological immunology and immune microenvironment. We discuss T-regulatory (Treg) and T helper 17 (Th17) cells dysfunction, the abnormal regulation of T helper 1(Th1) and T helper 2 (Th2) cells, macrophages, and their related cytokines as key activators in CP/CPPS. In addition, we discuss the roles of Treg and Th17 cells, Th1 and Th2 cells, and related cytokines in modulating prostate cancer progression. This review highlights the concept that immune cells and cytokines provide a research strategy for the etiology of CP/CPPS and offer potentially promising targets for the treatment of prostate cancer.
Persistent Identifierhttp://hdl.handle.net/10722/293122
ISSN
2023 Impact Factor: 2.1
2023 SCImago Journal Rankings: 0.586
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLiu, Yuqian-
dc.contributor.authorMikrani, Reyaj-
dc.contributor.authorXie, Dianyou-
dc.contributor.authorWazir, Junaid-
dc.contributor.authorShrestha, Sajan-
dc.contributor.authorUllah, Rahat-
dc.contributor.authorBaig, Mirza Muhammad Faran Ashraf-
dc.contributor.authorAhmed, Abrar-
dc.contributor.authorSrivastava, Prateek Kumar-
dc.contributor.authorThapa, Kedar Bahadur-
dc.contributor.authorZhou, Xiaohui-
dc.date.accessioned2020-11-19T09:02:01Z-
dc.date.available2020-11-19T09:02:01Z-
dc.date.issued2020-
dc.identifier.citationFundamental and Clinical Pharmacology, 2020, v. 34, n. 2, p. 160-172-
dc.identifier.issn0767-3981-
dc.identifier.urihttp://hdl.handle.net/10722/293122-
dc.description.abstract© 2019 Société Française de Pharmacologie et de Thérapeutique Prostate cancer and prostatitis are both significant health concerns. A large number of studies have established that the occurrence of the two is closely related. However, the most common prostatitis, type III chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS), is reported to not correlate with the occurrence of prostate cancer. Although the etiology of CP/CPPS is unknown, it may be related to the autoimmune mechanism favored by most studies. Manipulating the immune system and targeting tumor microenvironment are promising new methods for the treatment of prostate cancer. Therefore, this review focuses on the immune cells and cytokines of CP/CPPS and prostate cancer from the perspective of biological immunology and immune microenvironment. We discuss T-regulatory (Treg) and T helper 17 (Th17) cells dysfunction, the abnormal regulation of T helper 1(Th1) and T helper 2 (Th2) cells, macrophages, and their related cytokines as key activators in CP/CPPS. In addition, we discuss the roles of Treg and Th17 cells, Th1 and Th2 cells, and related cytokines in modulating prostate cancer progression. This review highlights the concept that immune cells and cytokines provide a research strategy for the etiology of CP/CPPS and offer potentially promising targets for the treatment of prostate cancer.-
dc.languageeng-
dc.relation.ispartofFundamental and Clinical Pharmacology-
dc.subjectTh1 cell-
dc.subjectT-regulatory cell-
dc.subjectTh2 cell-
dc.subjectmacrophage-
dc.subjectChronic prostatitis/chronic pelvic pain syndromes-
dc.subjectprostate cancer-
dc.subjectTh17 cell-
dc.titleChronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/fcp.12517-
dc.identifier.pmid31642541-
dc.identifier.scopuseid_2-s2.0-85075021565-
dc.identifier.volume34-
dc.identifier.issue2-
dc.identifier.spage160-
dc.identifier.epage172-
dc.identifier.eissn1472-8206-
dc.identifier.isiWOS:000495785500001-
dc.identifier.issnl0767-3981-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats